Curriculum Vitae

Neal R. Swerdlow, M.D., Ph.D.

Professional Appointment: 7/00-present: Professor of Psychiatry University of California, San Diego, La Jolla, CA 7/94-7/00: Associate Professor 7/91-7/94: Assistant Professor Academic Training: 7/87-7/91: Department of Psychiatry, UCSD, La Jolla, CA; Research Track Resident 7/86-7/87: Mercy Hospital and Medical Center, San Diego, CA; Internship 9/81-6/86: University of California, San Diego Medical Scientist Training Program: School of Med and Dept of Neuroscience; MD/PhD degree awarded 6/86 9/76-11/80: Amherst College, Amherst, MA; B.A. Neuroscience, Psychology; Summa Cum Laude Research Training: 7/87-6/91: Research Resident, UCSD Dept of Psychiatry 6/81-6/86: Graduate Student, UCSD Dept of Neurosci, AV Davis Ctr for Behav Neurobiol, Salk Inst and Div of Preclin Neurosci, Scripps Clin Res Fnd, La Jolla, CA (Dr. G.F. Koob) 11/80-6/81: Neuroscience Research Fellow, Amherst College, Amherst, MA 6/80-9/80: Research Asst, Brain Research Institute, UCLA (Dr. L. Kruger) 6/79-6/80: Neuroscience Honors Thesis Research, Amherst College 6/78-1/79: Research Asst, Brain Research Institute, UCLA, CA (Dr. L. Kruger) 3/78-6/78: Research Asst, Dept Neuroscience, Amherst College 11/77-2/78: Research Asst, Dept Psychology, UC Davis (Dr. L. Chalupa) 6/77-9/77: Research Asst, Dept Neurophysiol, VAMC, Sepulveda, CA (Dr. D. McGinty) Major Academic Responsibilities: 6/14 - present: Vice Chair, Education & Training 9/09 - present: Director, UCSD Psychiatry Research Residency Track 7/91-1/07: Director, Medical Student Clerkship and Electives, UCSD Department of Psychiatry Scientific and Medical Advisory Boards / Professional Committees: Deputy Director, Consortium on the Genetics of Schizophrenia (COGS), 2003-present Chair, ACNP Program Committee, 12/08-12/09 (Co-Chair, ACNP Program Committee, 12/07-12/08) Chair, Scientific Advisory Board, Tourette Syndrome Association, 1996-2005 (member '93-96, '06-‘12) Chair, Medical Advisory Board, NAMI, San Diego, 2000-2006 (Board of Directors, 1996-2000) Chair, NIMH Special Review Committee (NIH Neurobiology Course Development), 7/2006 Chair, NIMH Special Review Committee (IFCN-1), 7/2000 Member, NIMH Special Review Committee (ZMH1 ERB-D (01) R) 10/2014 Member, NIMH Special Review Committee (ZMH1 ERB-S (04)) 2/2014 Member, NIMH Special Review Committee (ZMH1 ERB-L-01, Silvio O. Conte Centers), 11/2013 Member, NIMH Special Review Committee (ZRG1) 6/2006, 6/2007, 6/2009, 1/2012 Member, NIMH Special Review Committee (MNPS) 6/2011 Member, NIMH Special Review Committee (ZMH1 BST-Q) 12/2006 Member, NIMH Special Review Committee (BDCN-A) 7/2006 Member, NINDS Special Review Committee (NSD-K) 7/2006 Member, NIMH Special Review Committee (ZMMI) 3/2006

Member, NIMH Special Review Committee (IFCN-1) 3/2000 Member, NIMH CIDAR Review Committee 10/2006 Member, Soc. Biological Psychiatry (SOBP) Program Committee, 1998-2014 Member, TSA Center of Excellence Review Committee, 2014 Co-Chair, 3rd International Scientific Symposium for Tourette Syndrome, 6/4-6/6, 1999 Co-Chair, Neurobiology of Disease Workshop, Society for Neuroscience, 1998 Organizing Committee, NIH Tourette Syndrome Therapeutics Workshop, 9/2006 Medical Investigation of Neurodevelopmental Disorders Institute (Past Member, SAB) Southern California Obsessive Compulsive Foundation (Past Member, SAB) Huntington’s Disease Society, San Diego Chapter (Past Member, MAB) Animal Research Committee, Amer. Col. Neuropsychopharmacology, 1995-7 Education and Training Committee, ACNP, 1998-2000 Credentials Committee, ACNP, 2003-5 Advocacy Committee, ACNP, 2005-8 Chair, Lilly Fellowship Award Committee, SOBP, 1999 (Co-Chair 6/98-6/99)) Membership Committee, SOBP, Chair, 2003-5 (Member 2001-3) Nominating Committee, SOBP, 2008-2010 George N. Thompson Award Committee, SOBP, 2005-7 Neurobiology of Disease Workshop Committee, Society for Neuroscience 1998-present Member (elected) UCSD Faculty Rights and Welfare Committee, 2005-2008 Editorial Boards Behavioral Neuroscience, Associate Editor (2007-2014) The Scientific World: Psychiatry, Editor (2005-2012) Psychopharmacology, Editorial Advisory Board (2001-present) Neuropsychopharmacology, Editorial Advisory Board (2002-present) Neuropsychopharmacology, Guest Editor, Dr. David Segal Memorial Issue, 2006 Pharmacology, Biochemistry and Behavior, Editorial Advisory Board (2002-present) Neurobiology of Disease, Editorial Advisory Board (2009-present) Behavioral Neuroscience, Consulting Editor (2002-6) CNS Spectrums, Editorial Advisory Board (1999-2003) Current Drug Targets - CNS & Neurological Disorder, Editorial Advisory Board (2004-6) Guest Editor, CNS Spectrums, Volume 4, Numbers 2 and 3. (1999) Grants / Fellowships: 7/14: NIMH R01 Award (Principal Investigator) MH59803 (Competitive Renewal) 6/13: NIMH R25 Award (Principal Investigator) MH101072 1/12: NIMH R01 Award (Principal Investigator) MH094320 6/11: NIMH R34 Award (Principal Investigator) MH093453 12/10: NIMH R01 Award (Principal Investigator) MH59803 (Competitive Renewal) 4/10: NIMH R01 Award (Co-Investigator) MH65571 (Competitive Renewal) 9/09: NIDA R03 Award (Principal Investigator) DA027483 7/08: NIMH R01 Award (Principal Investigator) MH68366 (Competitive Renewal) 7/06: NIMH R01 Award (Principal Investigator) MH53484 (Competitive Renewal) 4/06: NIMH RO1 Award (Co-Investigator) MH52885 (Competitive Renewal) 9/05: NIMH R25 Award (Principal Investigator) MH76768 4/05: NIGMS R25 Award (Co-Investigator) GM074118 5/04: NIMH R01 Award (Principal Investigator) MH69589 10/03: NIMH R01 Award (Principal Investigator) MH59803 (Competitive Renewal) 7/03: NIMH R21 Award (Co-Investigator) MH68611

7/03: NIMH R01 Award (Principal Investigator) MH68366 4/03: NIMH R01 Award (Co-Investigator) MH65571 3/03: NIMH R01 Award (Co-Investigator) MH42228 (Competitive Renewal) 11/01: NIMH K02 Award (Principal Investigator) MH01436 (Competitive Renewal) 11/00: NIMH R01 Award (Principal Investigator) MH53484 (Competitive Renewal) 11/99: NIMH RO1 Award (Co-Investigator) MH52885 (Competitive Renewal) 6/99: NINDS R13 Award (Principal Investigator) NS38340 4/99: NIMH RO1 Award (Principal Investigator) MH59803 2/99: M.I.N.D. Institute Research Award in Neurodevelopmental Disorders 3/97: California Department of Mental Health Award (Principal Investigator) State Senate Bill #472 2/97: NIMH K02 Award MH 01436 (Principal Investigator) 12/96: NIMH R01 Award (Principal Investigator) MH 53484 7/96: NIMH R03 Award (Principal Investigator) MH 54621 7/95: NARSAD Independent Investigator Award 1/95: NIMH RO1 Award (Co-Investigator) MH52885 3/93: Tourette Syndrome Association Research Award 2/93: Alfred P. Sloan Foundation Research Fellowship Award 7/92: NIMH R37 Award (Co-Investigator) MH42228 7/92: Scottish Rite Schizophrenia Research Award 7/92: NIMH R29 Award (Principal Investigator) MH48381 9/84: Scottish Rite Schizophrenia Graduate Research Fellowship 6/84: Parkinson's Disease Fnd Med Student Research Fellowship 11/83: Grant-in-Aid, Sigma Xi Scientific Research Society 6/83: Parkinson's Disease Foundation Med Student Research Fellowship 1/83: Medical Scientist Training Fellowship, N.I.H. 6/82: Summer Research Fellowship, School of Med., UCSD 6/81: Woodruff-Simpson Fellowship for Medical Sciences, Amherst College Awards / Honors: 5/12: 2012 Award for Research, American Psychiatric Association 6/10: Commencement Speaker, UCSD Graduate Studies 2/06: Champion of Children Award, Tourette Syndrome Association 12/02: The Joel Elkes International Award in Translational Research, ACNP 12/99: Elected Fellow, American College of Neuropsychopharmacology 5/98: Early Contribution Award, American Psychiatric Electrophysiology Association 3/98: Anxiety Disorders Association of America, Young Investigator Award 2/96: Chair, Scientific Advisory Board, Tourette Syndrome Association 7/95: Independent Invest. Award, Nat Alliance for Research on Schizophrenia and Depression (NARSAD) 12/93: Elected Member, American College of Neuropsychopharmacology 4/93: Board Certification, American Board of Psychiatry and Neurology 8/92: Judith Silver Young Scientist Award, National Alliance for the Mentally Ill 6/91: Chairman's Research Award, Department of Psychiatry, UCSD School of Medicine 4/91: N.E. Miller New Investigator Award, The Academy of Behavioral Medicine Research 3/91: Dista Travel Fellowship Award, Society of Biological Psychiatry 2/91: APA Kempf Fund Award for Research Development in Psychobiological Psychiatry 2/91: Young Investigator Award, International Congress on Schizophrenia Research 2/90: Young Investigator Award, NARSAD 10/89: Travel Fellowship Award, American College of Neuropsychopharmacology 8/89: 3rd place, Bingham Competition for Scholarship in Schizophrenia 8/89: UpJohn/NIMH Outstanding Psychiatric Resident Award

8/89: Honorable Mention, Central Neuropsych Assoc Menninger Award 2/89: Honorable Mention, APA/Dista Products Resident Research Award 11/88: Laughlin Fellowship, American College of Psychiatrists 5/87: Prentiss Award for Med Research, Mercy Hospital and Medical Center, 2nd and 3rd place 6/81: Phi Beta Kappa; Sigma Xi; Amherst Col PI on Investigator Initiated Research Awards from Private Industry - examples include: Allergan Pharmaceuticals - Phase 1, Single-Center, Randomized, Double-Blind, Single-Dose, Placebo- Controlled, Two-Period Crossover Study to Explore the Safety and Efficacy of *** ****** 100 mg capsule on ******* Pfizer Pharmaceuticals - Effects of nicotine on P50 suppression in schizophrenia patients AstraZeneca Pharmaceuticals - Effects of quetiapine in cross-species models of antipsychotic efficacy Repligen Pharmaceuticals - Effects of ****** on prepulse inhibition of startle in rats Kadmus Pharmaceuticals - Effects of ****** on prepulse inhibition of startle in rats Servier Pharmaceuticals - Effects of ****** on prepulse inhibition of startle in rats Data Safety and Monitoring Boards 1/06: "Stress, blood pressure, and ethnicity research study," (HL 36005) (J. Dimsdale, PI) 1/07: “Deep brain stimulation (DBS) for severe, persistent and refractory Tourette’s syndrome,” (HIC#0605001493), and “Medtronic Activa Deep Brain Stimulation System for use in the treatment of severe, persistent and refractory Tourette’s syndrome,” (FDA IDE# G060112/S3) (J. Leckman, PI) Professional Organizations: American College of Neuropsychopharmacology Society for Biological Psychiatry Society for Neuroscience Sigma Xi Phi Beta Kappa NY Academy of Sciences Clinical Activities: 7/91-7/98: Attending Psychiatrist, Genetically Handicapped Person's Program (GHPP) 7/91-7/98: Attending Psychiatrist, Obsessive Compulsive Disorder Program, UCSD 7/91 - present: Clinical Attending Staff, UCSD Medical Center, San Diego, CA Clinical Licensure: Medical Board of California, Licensure 2/1988 - present Board Certification, American Board of Psychiatry and Neurology, 4/93 Teaching Activities: Director, Psychiatry Research Residency Track 1/10 – present (lead monthly Resident seminar; career mentorship with 4-6 residents/y)) Course Director, UCSD Psychiatry Core Clerkship, 7/91 - 1/07 (taught 6-week Clerkship 124 times; provided > 600 lectures) Course Director, Neuroscience 221 (2005 and 2008 Neurosciences elective seminar) Course Director, Neuroscience 232 (2006-7, "Neuroscience at the Boundaries of Psychiatry and Neurology") Section leader, Pharmacology 250 (2005-7, "Systems Pharmacology and Translational Biology") Director, UCSD Psychiatry Electives Program (7/91 – 6/2006) Regular lecturer: Psychology 188, Psychiatry 401, Psychiatry Residency Lecture Series, Child Psychiatry Fellows Lecture Series, UCSD OCD/TS Clinic lecture series

Bibliography H-Index (as of 10/14) = 67

Peer-Reviewed Papers (does not include > 300 published abstracts and proceedings): 1. Sorenson CA, Swerdlow NR. The effects of tail pinch on the acoustic startle response in rats. Brain Res 247, 105-113, 1982. 2. Van der Kooy D, Swerdlow NR, Koob GF. Paradoxical reinforcing properties of apomorphine: Effects of nucleus accumbens and area postrema lesions. Brain Res 259, 111-118, 1983. 3. Swerdlow NR, van der Kooy D, Koob GF, Wenger JR. Cholecystokinin produces conditioned place-aversions, not place- preferences, in food-deprived rats: evidence against involvement in satiety. Life Sciences, 32, 2087-2093, 1983.

4. Swerdlow NR, Swanson LW, Koob GF. Electrolytic lesions of the substantia innominata and lateral preoptic area attenuate the 'supersensitive' locomotor response to apomorphine resulting from denervation of the nucleus accumbens. Brain Res 306, 141-148, 1984. 5. Swerdlow NR, Swanson LW, Koob GF. Substantia innominata: critical link in the behavioral expression of mesolimbic dopamine stimulation in the rat. Neurosci Letters 50, 19-24, 1984. 6. Swerdlow NR, Koob GF. The neural substrates of apomorphine-stimulated locomotor activity following denervation of the nucleus accumbens. Life Sci 35, 2537-2544, 1984. 7. Koob GF, Swerdlow N, Seeligson M, Eaves M, Sutton R, Rivier J, Vale W. Effects of alpha-flupenthixol and naloxone on CRF-induced locomotor activation Neuroendocrinol 39, 459-464, 1984. 8. Swerdlow NR, Koob GF. Restrained rats learn amphetamine- conditioned locomotion, but not place preference. Psychopharm 84, 163-166, 1984. 9. Swerdlow NR, Koob GF. Separate neural substrates of the locomotor-activating properties of amphetamine, heroin, caffeine, and corticotropin releasing factor (CRF) in the rat. Pharmacol Biochem Behav 23, 303-307, 1985.

10. Swerdlow NR, Vaccarino F, Koob GF. Effects of naloxone on heroin-, amphetamine- and caffeine-stimulated locomotor activity in the rat. Pharmacol Biochem Behav 23, 499-501, 1985.

11. Swerdlow NR, Lee D, Koob GF, Vaccarino FJ. Effects of chronic dietary lithium on behavioral indices of dopamine denervation supersensitivity in the rat. J Pharm Exp Ther 235, 324-329, 1985.

12. Vaccarino FJ, Amalric M , Swerdlow NR, Koob GF. Blockade of amphetamine but not opiate-induced locomotion following antagonism of dopamine function in rat. Pharmacol Biochem Behav 24, 61-65, 1986.

13. Swerdlow NR, Koob GF, Aldenhoff JB. The effects of verapamil on the locomotor-activating properties of corticotropin releasing factor (CRF) in the rat. Psychoneuroendocrinol 11, 237-240, 1986.

14. Swerdlow NR, Geyer MA, Vale WW, Koob GF. Corticocotropin releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide. Psychopharm 88, 147-152, 1986.

15. Bakhit C, Swerdlow N. Behavioral changes following central injection of cysteamine in rats. Brain Res 365, 159-163, 1986.

16. Swerdlow NR, Braff DL, Geyer MA, Koob GF. Central dopamine hyperactivity in rats mimics abnormal acoustic startle response in schizophrenics. Biol Psychiat 21, 23-33, 1986.

17. Swerdlow NR, Vaccarino FJ, Amalric M, Koob GF. The neural substrates for the motor-activating properties of psychostimulants: A review of recent findings. Pharmacol Biochem Behav 25, 233-248, 1986.

18. Downs NS, Britton KT, Gibbs DM, Koob GF, Swerdlow NR. Supersensitive endocrine response to physostigmine in dopamine-depleted rats: A model of depression? Biol Psychiat 21, 775-786, 1986.

19. Blasco TA, Lee D, Amalric M, Swerdlow NR, Smith NT, Koob GF. The role of the nucleus raphe pontis and the caudate nucleus in alfentanil rigidity in the rat. Brain Res 386, 280-286, 1986.

20. Amalric M, Blasco TA, Smith NT, Lee DE, Swerdlow NR, Koob GF. Catatonia produced by alfentanil is reversed by methylnaloxonium microinjections into the brain. Brain Res 386, 287-295, 1986.

21. Swerdlow NR, Koob GF. Dopamine, schizophrenia, mania and depression: Toward a unified hypothesis of cortico-striato-pallido-thalamic function. Behav Brain Sci 10, 197-245, 1987.

22. Amalric M, Koob GF, Creese I, Swerdlow NR. "Selective" D-1 and D-2 receptor antagonists fail to differentially alter supersensitive locomotor behavior in the rat. Life Sci 39, 1985-1993, 1986.

23. Swerdlow NR, Amalric M , Koob GF. Nucleus accumbens opiate-dopamine interactions and locomotor activation in the rat: Evidence for a pre-synaptic locus. Pharmacol Biochem Behav 26, 765-769, 1987. 24. Swerdlow NR, Koob GF. Lesions of the dorsomedial nucleus of the thalamus, medial prefrontal cortex and pedunculopontine nucleus: Effects on locomotor activity mediated by nucleus accumbens-ventral pallidal circuitry. Brain Res 412, 233-243, 1987.

25. Tazi A, Swerdlow NR, LeMoal M, Rivier J, Vale W, Koob GF. Behavioral activation by CRF: Evidence for the involvement of the ventral forebrain. Life Sci 41, 41-49, 1987.

26. Swerdlow NR, Haubrich R. Aggressive treatment of a patient with the acquired immunodeficiency syndrome. Ann Internal Med 597, 1987.

27. Weinger MB, Swerdlow NR, Millar WL. Acute postoperative delirium and extrapyramidal signs in a previously healthy parturient. Anesth Analg 67, 291-295, 1988.

28. Swerdlow NR. Ventral striato-pallidal circuitry and the neural substrates of dopamine-stimulated locomotor activity in the rat. Doctoral thesis dissertation, Univ California San Diego, 1986.

29. Gold LH, Swerdlow NR, Koob GF. The role of mesolimbic dopamine in conditioned locomotion produced by amphetamine. Behav Neurosci 102, 544-552, 1988.

30. Swerdlow NR, Koob GF. Norepinephrine stimulates behavioral activation in rats following depletion of nucleus accumbens dopamine. Pharmacol Biochem Behav 33: 595-599, 1989.

31. Pulvirenti L, Swerdlow NR, Koob GF. Microinjections of a glutamate antagonist into the nucleus accumbens reduces psychostimulant locomotion in rats. Neurosci Letters 103: 213-218, 1989.

32. Swerdlow NR, Britton KT, Koob GF. Potentiation of acoustic startle by corticotropin-releasing factor (CRF) and by fear are both reversed by alpha-helical CRF (9-41). Neuropsychopharm 2: 285-292, 1989.

33. Swerdlow NR, Andia AM. Trazodone-fluoxetine combination for treatment of obsessive compulsive disorder. Am J Psychiatry 146:1637, 1989.

34. Swerdlow NR, Gierz M, Berkowitz A, Nemiroff R, Lohr J. Electroconvulsive therapy in a patient with severe tic and major depressive episode. J Clin Psychiat 51: 34-35, 1990.

35. Swerdlow NR, Koob GF. Toward a unified hypothesis of cortico-striato-pallido-thalamic function? Behav Brain Sci 13: 172-182, 1990.

36. Swerdlow NR, Mansbach RS, Geyer MA, Pulvirenti L, Koob GF, Braff DL. Amphetamine disruption of prepulse inhibition of acoustic startle is reversed by depletion of mesolimbic dopamine. Psychopharm 100: 413-416, 1990.

37. Swerdlow NR, Braff DL, Masten VL, Geyer MA. Schizophrenic-like sensorimotor gating abnormalities in rats following dopamine infusion into the nucleus accumbens. Psychopharm 101:414-420, 1990. 38. Davis M, Mansbach RS, Swerdlow NR, Campeau S, Braff DL, Geyer MA. Apomorphine disrupts the inhibition of acoustic startle induced by weak prepulses in rats. Psychopharm 102: 1-4, 1990. 39. Geyer MA, Swerdlow NR, Mansbach RS, Braff DL. Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res Bull 25: 485-498, 1990. 40. Swerdlow NR, Braff DL, Geyer MA. GABAergic projection from nucleus accumbens to ventral pallidum mediates dopamine-induced sensorimotor gating deficits of acoustic startle in rats. Brain Research 532: 146-150, 1990.

41. Koob GF, Cole BJ, Swerdlow NR, Le Moal M, Britton KT. Stress, performance and arousal: Focus on CRF. NIDA Research Monograph 97: 163-176, 1990.

42. Swerdlow NR, Keith VA, Braff DL, Geyer MA. Effects of spiperone, raclopride, SCH 23390 and clozapine on apomorphine inhibition of sensorimotor gating of the startle response in the rat. J Pharmacol Exp Ther 256: 530-536, 1991. 43. Swerdlow NR, Caine SB, Geyer MA. Opiate-dopamine interactions in the neural substrates of acoustic startle gating in the rat. Prog Neuro-Psychopharm Biol Psychiat 15:415-426, 1991. 44. Swerdlow NR. Neuropsychology of schizophrenia: The "hole" thing is wrong. Behavioral and Brain Sciences 14, 51-53, 1991. 45. Swerdlow NR, Hauger R, Irwin M, Koob GF, Britton KT, Pulvirenti L. Endocrine, immune and neurochemical changes in rats during withdrawal from chronic amphetamine intoxication. Neuropsychopharm 5, 23-31, 1991.

46. Caine SB, Geyer MA, Swerdlow NR. Carbachol infusion into the dentate gyrus disrupts sensorimotor gating of startle in the rat. Psychopharm 105, 347-354, 1991.

47. Pulvirenti L, Swerdlow NR, Koob GF. Nucleus accumbens NMDA antagonist decreases locomotor activity produced by cocaine, heroin or accumbens dopamine, but not caffeine. Pharmacol Biochem Behav 40: 841-845, 1991. 48. Swerdlow NR, Caine SB, Braff DL, Geyer MA. The neural substrates of sensorimotor gating of the startle reflex: A review of recent findings and their implications. J Psychopharmacol 6: 176-190, 1992. 49. Downs NS, Swerdlow NR, Zisook S. The relationship of affective illness and personality disorders in psychiatric outpatients. Ann Clin Psychiat 4: 87-94, 1992. 50. Swerdlow NR, Caine SB, Geyer MA. Regionally selective effects of intracerebral dopamine infusion on sensorimotor gating of the startle reflex in rats. Psychopharmacol 108: 189-195, 1992. 51. Caine SB, Geyer MA, Swerdlow NR. Hippocampal modulation of acoustic startle and prepulse inhibition in rats. Pharmacol Biochem Behav 43: 1201-1208, 1992. 52. Swerdlow NR, Geyer MA. Prepulse inhibition of acoustic startle in rats after lesions of the pedunculopontine tegmental nucleus. Behav Neurosci 107: 104-117, 1993. 53. Swerdlow NR, Benbow CH, Zisook S, Geyer MA, Braff DL. A preliminary assessment of sensori-motor gating in patients with Obsessive Compulsive Disorder. Biol Psychiatry 33: 298-301, 1993. 54. Swerdlow NR, Geyer MA. Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharmacol Biochem Behav 44: 741-744, 1993.

55. Swerdlow NR, Braff DL, Taaid N, Geyer MA. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 51:139-154, 1994.

56. Swerdlow NR, Koob GF, Cador M, Lorang M, Hauger RL. Pituitary-adrenal axis responses to acute amphetamine in the rat. Pharmacol Biochem Behav 45:629-637, 1993.

57. Wan FJ, Swerdlow NR. Intra-accumbens infusion of quinpirole impairs sensorimotor gating of acoustic startle in rats. Psychopharm 113: 103-109, 1993.

58. Swerdlow NR. Dopamine and depression: Circuitous logic? Biol Psychiatry 33: 757-758, 1993. 59. Swerdlow NR, Auerbach P, Monroe SM, Hartston H, Geyer MA, Braff DL. Men are more inhibited than women by weak prepulses. Biol Psychiatry 34: 253-260, 1993. 60. Swerdlow NR, Britton KT. Alphaxalone, a steroid anesthetic, inhibits the startle-enhancing effects of corticotropin releasing factor, but not strychnine. Psychopharm 115: 141-146, 1994. 61. Kodsi MH, Swerdlow NR. Quinolinic acid lesions of the ventral striatum reduce sensorimotor gating of acoustic startle in rats. Brain Research 643:59-65, 1994. 62. Wan FJ, Geyer MA, Swerdlow NR. Accumbens D2 modulation of sensorimotor gating in rats: Assessing anatomical localization. Pharmacol Biochem Behav 49: 155-163, 1994. 63. Swerdlow NR, Zisook D, Taaid N. Seroquel (ICI 204,636) restores prepulse inhibition of acoustic startle in apomorphine-treated rats: Similarities to clozapine. Psychopharm 114: 675-678, 1994. 64. Swerdlow NR, Filion D, Geyer MA, Braff DL. "Normal" personality correlates of sensorimotor, cognitive and visuospatial gating. Biol Psychiatry 37: 286-299, 1995. 65. Swerdlow NR, Paulsen J, Braff DL, Butters N, Geyer MA, Swenson MR. Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's Disease. J Neurol Neurosurg Psychiatry 58: 192-200, 1995.

66. Bakshi VP, Swerdlow NR, Geyer MA. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 271: 787-794, 1994.

67. Caine SB, Geyer MA, Swerdlow NR. Effects of D3/D2 dopamine receptor agonists and antagonists on prepulse inhibition of acoustic startle in the rat. Neuropsychopharm 12: 139-145, 1995.

68. Swerdlow NR. Serotonin, obsessive compulsive disorder and the basal ganglia. International Review of Psychiatry 7:115-129, 1995.

69. Paulsen JS, Butters N, Sadek JR, Johnson SA, Salmon DP, Swerdlow NR, Swenson MR. Distinct cog-nitive profiles of cortical and subcortical dementia in advanced illness. Neurology 45: 951-956, 1995.

70. Filoteo JV, Delis DC, Roman MJ, Demadura T, Ford E, Butters N, Salmon DP, Paulsen J, Schults CW, Swenson M, Swerdlow N. Visual attention and perception in patients with Huntington’s Disease: Com-parisons with other subcortical and cortical dementias. J Clin Exper Neuropsychol 17: 654-667, 1995. 71. Swerdlow NR, Lipska BK, Weinberger DR, Braff DL, Jaskiw GE, Geyer MA. Increased sensitivity to the sensorimotor gating-disruptive effects of apomorphine after lesions of medial prefrontal cortex or ventral hippocampus in adult rats. Psychopharmacology 122: 27-34, 1995.

72. Lipska BK, Swerdlow NR, Geyer MA, Jaskiw GE, Braff DL, Weinberger DR. Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology 122: 35-43, 1995. 73. Swerdlow NR, Geyer MA, Perry W, Cadenhead K, Braff DL. Drug screening in "normal" controls. Biol Psychiat 38: 123-124, 1995.

74. Braff DL, Swerdlow NR, Geyer MA. Gating and habituation deficits in the schizophrenia disorders. Clin Neurosci 3: 131-139, 1995.

75. Swerdlow NR. Don't leave the "un" off of "consciousness". Behav Brain Sci 18: 699-700, 1995. 76. Bakshi VP, Geyer MA, Taaid N, Swerdlow NR. A comparison of the effects of amphetamine, strych-nine and caffeine on prepulse inhibition and latent inhibition. Behav Pharmacol 6: 801-809, 1995. 77. Kodsi MH, Swerdlow NR. Prepulse inhibition in the rat is regulated by ventral and caudodorsal striato-pallidal circuitry. Behavioral Neuroscience 109: 912-928, 1995. 78. Wan FJ, Geyer MA, Swerdlow NR. Presynaptic dopamine-glutamate interactions in the nucleus accumbens regulate sensorimotor gating. Psychopharmacology 120: 433-441, 1995. 79. Kodsi MH, Swerdlow NR. Ventral pallidal GABA-A receptors regulate prepulse inhibtion of acoustic startle. Brain Research 684: 26-35, 1995. 80. Wan FJ, Taaid N, Swerdlow NR. Do D1/D2 interactions regulate prepulse inhibition in rats? Neuropsychopharm 14: 265-274, 1996. 81. Clementz BA, Farber RH, Lam MN, Swerdlow NR. Ocular motor responses to unpredictable and predictable smooth pursuit stimuli among patients with obsessive-compulsive disorder. J Psychiat Neurosci 21: 21-28, 1996.

82. Swerdlow NR, Braff DL, Hartston H, Perry W, Geyer MA. Latent inhibition in schizophrenia. Schiz Res 20: 91-103, 1996.

83. Wan FJ, Swerdlow NR. Sensorimotor gating in rats is regulated by different dopamine-glutamate interactions in the nucleus accumbens core and shell subregions. Brain Res 722: 168-176, 1996.

84. Swerdlow NR, Magulac M, Filion D, Zinner S. Visuospatial priming and latent inhibition in children and adults with Tourette’s Disorder. Neuropsychology 10: 485-494, 1996.

85. Swerdlow NR, Bakshi V, Geyer MA. Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther 279: 1290-1299, 1996.

86. Wan FJ, Swerdlow NR. The basolateral amygdala regulates sensorimotor gating of acoustic startle in the rat. Neuroscience 76: 715-724, 1997.

87. Wan FJ, Caine SB, Swerdlow NR. The ventral subiculum modulation of prepulse inhibition is not mediated via dopamine D2 or nucleus accumbens non-NMDA glutamate receptor activity. Eur J Pharmacol 314: 9-18, 1996. 88. Knowlton BJ, Squire LR, Paulsen JS, Swerdlow NR, Swenson M, Butters N. Dissociations within nondeclarative memory in Huntington’s Disease. Neuropsychology 10: 538-548, 1996. 89. Kieburtz K, Penney JB, Como P, Ranen N, Shoulson I, Feigin A, Abwender D, Greenamyre JT, Higgins D, Marshall FJ, Goldstein J, Steinberg K, Shih C, Richard I, Hickey C, Zimmerman C, Orme C, Claude K, Oakes D, Sax DS, Kim A, Hersch S, Jones R, Auchus A, Olsen D, BisseyBlack C, Rubin A, Schwartz R, Dubinsky R, Mallonee W, Gray C, Godfrey N, Suter G, Shannon KM, Stebbins GT, Jaglin JA, Marder K, Taylor S, Louis E, Moskowitz C, Thorne D, Zubin N, Wexler N, Swenson MR, Paulsen J, Swerdlow N, Albin R, Wernette C, Walker F, Hunt V, Roos RAC, Young AB, Koroshetz W, Bird E, Meyers R, Cudkowicz M, Guttman M, StCyr J, Burkholder J, Lundin A, Ashizawa T, Jankovic J, Siemers E, Quaid K, Martin W, SanchezRamos J, Facca A, Rey G, Suchowersky O, Rohs G, Klinek ML, Ross C, Bylsma FW, Sherr M, Hayden M, Raymond L, Clark C, Kremer B. Unified Huntington's disease rating scale: Reliability and consistency. Movement Disorders 11, 136-142, 1996. 90. Swerdlow NR, Hartman PL, Auerbach PP. Changes in sensorimotor inhibition across the menstrual cycle: Implications for neuropsychiatric disorders. Biol Psychiatry 41: 452-460, 1997.

91. Farber RH, Clementz BA, Swerdlow NR. Characteristics of open- and closed-loop smooth pursuit responses among obsessive-compulsive disorder, schizophrenia and nonpsychiatric individuals. Psychophysiol 34: 157-162, 1997. 92. Feifel D, Swerdlow NR. The modulation of sensorimotor gating deficits by mesolimbic cholecystokinin. Neurosci Lett 229: 5-8, 1997. 93. Kodsi MH, Swerdlow NR. Regulation of prepulse inhibition by ventral pallidal projections. Brain Res Bull 43: 219-228, 1997. 94. Braff DL, Swerdlow NR. Neuroanatomy of schizophrenia. Schizophrenia Bull 23: 509-512, 1997.

95. Kodsi MH, Swerdlow NR. Reduced prepulse inhibition after electrolytic lesions of nucleus accumbens subregions in the rat. Brain Res 773: 45-52, 1997.

96. Kodsi MH, Swerdlow NR. Mitochondrial toxin 3-nitropropionic acid produces startle reflex abnormalities and striatal damage in rats that model some features of Huntington’s Disease. Neurosci Lett 231: 103-107, 1997. 97. Swerdlow NR, Varty GB, Geyer MA. Discrepant findings of clozapine effects on prepulse inhibition of startle: Is it the route or the rat ? Neuropsychopharmacol 18: 50-56, 1998. 98. Feifel D, Minor KL, Dulawa S, Swerdlow NR. The effects of intra-accumbens neurotensin on sensorimotor gating. Brain Res 760: 80-84, 1997. 99. Swerdlow NR. Startle in Tourette’s Syndrome (Letter) Biol Psychiatry 44: 935-936, 1998.

100. Bakshi VP, Swerdlow NR, Braff DL, Geyer MA. Reversal of isolation rearing-induced deficits in prepulse inhibition by seroquel and olanzapine. Biol Psychiatry 43: 436-445, 1998.

101. Swerdlow NR. What role models? Behavioural Pharmacol 9: 529-531, 1998. 102. Swerdlow NR, Geyer MA. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophenia Bull 24: 285-301, 1998. 103. Hart S, Zreik M, Carper R, Swerdlow NR. Localizing haloperidol effects on sensorimotor gating in a predictive model of antipsychotic potency. Pharmacol Biochem Behav 61: 113-119, 1998. 104. Swerdlow NR, Taaid N, Oostwegel JL, Randolph E, Geyer MA. Towards a cross-species pharmacology of sensorimotor gating: Effects of amantadine, bromocriptine, pergolide and ropinirole on prepulse inhibition of acoustic startle in rats. Behavioural Pharmacol 9:389-396, 1998.

105. Roman MJ, Delis DC, Filoteo JV, Demdura TL, Paulsen J, Swerdlow NR, Swenson MR, Salmon D, Butters N, Shults C. Is there a “subcortical” profile of attentional dysfunction? A comparison of patients with Huntington’s and Parkinson’s diseases on a global-local focused attention task, J Clin Exp Neuropsychol 20: 873-884, 1998.

106. Swerdlow NR, Bakshi V, Waikar M, Taaid N, Geyer MA. Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharm 140: 75-80, 1998.

107. Farber RH, Swerdlow NR, Clementz BA. Saccadic performance characteristics and the behavioral neurology of Tourette’s syndrome. J Neurol Neurosurg Psychiatry 66:305-12, 1999.

108. Swerdlow NR, Hartston HJ, Hartman PL. Enhanced visual latent inhibition in Obsessive Compulsive Disorder. Biol Psychiatry 45: 482-488, 1999.

109. Martinez ZA, Ellison GD, Geyer MA, Swerdlow NR. Effects of sustained cocaine exposure on sensorimotor gating of startle in rats. Psychopharmacol 142: 253-260, 1999.

110. Swerdlow NR, Young AB. Neuropathology in Tourette Syndrome. CNS Spectrums 4: 65-74, 1999.

111. Hartston HJ, Swerdlow NR. Visuospatial priming and Stroop performance in patients with Obsessive Compulsive Disorder. Neuropsychology 13: 447-457, 1999.

112. Martinez ZA, Ellison GD, Geyer MA, Swerdlow NR. Effects of sustained phencyclidine exposure on sensorimotor gating of startle in rats. Neuropsychopharm 21: 28-39, 1999.

113. Swerdlow NR, Zinner S, Farber RH, Seacrist C, Hartston H. Symptoms in Obsessive Compulsive Disorder and Tourette Syndrome: A spectrum ? CNS Spectrums 4: 21-33, 1999.

114. Braff DL, Swerdlow NR, Geyer MA. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am J Psychiatry 156: 596-602, 1999.

115. Swerdlow NR. Tourette Syndrome: Lessons from a model. CNS Spectrums 4: 16-17, 1999. 116. Swerdlow NR, Braff DL, Geyer MA. Cross-species studies of sensorimotor gating of the startle reflex. Ann NY Acad Sci 877: 202-216, 1999. 117. Cadenhead KS, Carasso BS, Swerdlow NR, Geyer MA, Braff DL. Prepulse inhibition and habituation of the startle response are stable neurobiological measures in a normal male population. Biol Psychiatry 45: 360-364, 1999.

118. Swerdlow NR, Geyer MA, Blumenthal TD, Hartman PL. Effects of discrete acoustic prestimuli on perceived intensity and behavioral responses to startling acoustic and tactile stimuli. Psychobiology 27: 547-556, 1999. 119. Feifel D, Moutier CY, Swerdlow NR. Attitudes toward psychiatry as a prospective career among students entering medical school. Am J Psychiatry 156:1397-1402, 1999. 120. Geyer MA, Swerdlow NR, Lehmann-Masten V, Teschendorf H-J, Traut M, Gross G. Effects of LU-111995 in three models of disrupted prepulse inhibition in rats. J Pharmacol Exp Ther 290:716-24, 1999. 121. Doan QT, Swerdlow NR. Preliminary findings with a new Vietnamese Stroop test. Perceptual and Motor Skills 89: 173-182, 1999. 122. Swerdlow NR, Geyer MA, Hartman PL, Sprock J, Auerbach PP, Cadenhead K, Perry W, Braff DL. Sex differences in sensorimotor gating of the human startle reflex: All smoke? Psychopharmacology 146: 228-232, 1999.

123. Martinez ZA, Halim ND, Oostwegel JL, Geyer MA, Swerdlow NR. Ontogeny of phencyclidine and apomorphine-induced startle gating deficits in rats. Pharmacol Biochem Behav 65: 449-457, 2000

124. Swerdlow NR, Taaid N, Halim N, Randolph E, Kim YK, Auerbach P. Hippocampal lesions enhance startle gating-disruptive effects of apomorphine in rats: A parametric assessment. Neuroscience 96: 523-536, 2000. 125. Swerdlow NR, Braff DL, Geyer MA. Animal models of deficient sensorimotor gating: What we know, what we think we know, and what we hope to know soon. Behav Pharmacol 11:185-204, 2000. 126. Swerdlow NR, Martinez ZA, Hanlon FM, Platten A, Farid M, Auerbach P, Braff DL, Geyer MA. Toward understanding the biology of a complex phenotype: Rat strain and substrain differences in the sensorimotor gating-disruptive effects of dopamine agonists. J Neuroscience 20: 4325-4336, 2000.

127. Martinez ZA, Oostwegel J, Geyer MA, Ellison GD, Swerdlow NR. “Early” and “late” effects of sustained haloperidol on apomorphine- and phencyclidine-induced sensorimotor gating deficits. Neuropsychopharm 23: 517-527, 2000. 128. Swerdlow NR, Eastvold A, Gerbranda T, Uyan KM, Hartman P, Doan Q, Auerbach P. Effects of caffeine on sensorimotor gating of the startle reflex in normal control subjects: Impact of caffeine intake and withdrawal. Psychopharm 151: 368-378, 2000.

129. Halim ND, Swerdlow NR. Distributed neurodegenerative changes 2 - 28 days after ventral hippocampal excitotoxic lesions in rats. Brain Research 873:60-74, 2000.

130. Farid M, Martinez ZA, Geyer MA, Swerdlow NR. Regulation of sensorimotor gating of the startle reflex by serotonin 2A receptors: ontogeny and strain differences. Neuropsychopharm 23: 623-632, 2000.

131. Cadenhead KS, Swerdlow NR, Shafer KM, Diaz M, Braff DL. Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: Evidence of inhibitory deficits. Am J Psychiatry 157:1660-1668, 2000. 132. Braff DL, Geyer MA, Light GA, Sprock J, Perry W, Cadenhead KS, Swerdlow NR. Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schiz Research 49:171-178, 2001.

133. Swerdlow NR, Eastvold A, Uyan KM, Ploum Y, Cadenhead K. Matching strategies for drug studies of prepulse inhibition in humans. Behav Pharmacol 12: 45-52, 2001.

134. Swerdlow NR. In Focus: PCP-induced PPI deficits in primates. NeuroReport 12: A3, 2001 (Invited Commentary).

135. Swerdlow NR, Hanlon FM, Henning L, Kim YK, Gaudet I, Halim ND. Regulation of sensorimotor gating in rats by hippocampal NMDA: Anatomical localization. Brain Res 898: 195-203, 2001.

136. Swerdlow NR, Geyer MA, Braff DL. Neural circuit regulation of prepulse inhibition of startle in the rat: Current knowledge and future challenges. Psychopharmacology 156: 194-215, 2001.

137. Swerdlow NR, Halim N, Hanlon FM, Platten A, Auerbach PP. Lesion size and amphetamine hyperlocomotion after neonatal ventral hippocampal lesions: More is less. Brain Res Bulletin 55:71-7, 2001. 138. Swerdlow NR, Karban B, Ploum Y, Sharp R, Geyer MA, Eastvold A. Tactile prepuff inhibition of startle in children with Tourette’s Syndrome: In search of an “fMRI-friendly” startle paradigm. Biological Psychiatry 50: 578-585, 2001.

139. Swerdlow NR, Platten A, Shoemaker J, Pitcher L, Auerbach P. Effects of pergolide on sensorimotor gating of the startle reflex in rats. Psychopharmacology 158: 230-240, 2001.

140. Swerdlow NR, Platten A, Kim YK, Gaudet I, Shoemaker J, Pitcher L, Auerbach P. Sensitivity to the dopaminergic regulation of prepulse inhibition in rats: Evidence for genetic, but not environmental determinants. Pharmacol Biochem Behav 70: 219-226, 2001. 141. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology 156: 117-154, 2001.

142. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: Normal subjects, patient groups, and pharmacological studies. Psychopharm 156: 234-258, 2001.

143. Martinez ZA, Platten A, Pollack E, Shoemaker J, Ro H, Pitcher L, Geyer MA, Swerdlow NR. “Typical” but not “atypical” antipsychotic effects on startle gating deficits in prepubertal rats. Psychopharmacology 161: 38-46, 2002. 144. Swerdlow NR, Eastvold A, Karban B, Ploum Y, Stephany N, Geyer MA, Cadenhead K, Auerbach PP. Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: Time course studies. Psychopharmacology 161: 189-201, 2002.

145. Swerdlow NR, Shoemaker JM, Stephany N, Wasserman L, Ro HJ, Geyer MA. Prestimulus effects on startle magnitude: Sensory or motor? Behavioral Neuroscience 116: 672-681, 2002.

146. Swerdlow NR, Shoemaker JM, Pitcher L, Platten A, Kuczenski R, Eleey CC, Auerbach P. Genetic differences in startle gating-disruptive effects of apomorphine: evidence for central mediation. Behavioral Neuroscience 116: 682-690, 2002. 147. Swerdlow NR, Stephany N, Shoemaker JM, Ross L, Wasserman LC, Talledo J, Auerbach PP. Effects of amantadine and bromocriptine on startle and sensorimotor gating: Parametric studies and cross-species comparisons. Psychopharmacology 164: 82-92, 2002.

148. Shoemaker JM, Pitcher L, Noh HR, Swerdlow NR. Quetiapine produces a prolonged reversal of the sensorimotor gating-disruptive effects of basolateral amygdala lesions in rats. Behavioral Neuroscience 117: 136-143, 2003. 149. Powell SB, Swerdlow NR, Pitcher LK, Geyer MA. Isolation rearing-induced deficits in prepulse inhibition and locomotor habituation are not potentiated by water deprivation. Physiology & Behavior 77: 55-64, 2002.

150. Swerdlow NR, Platten A, Hanlon FM, Martinez ZA, Printz MP, Auerbach P. Sensitivity to sensorimotor gating-disruptive effects of apomorphine in two outbred parental rat strains and their F1 and N2 progeny. Neuropsychopharmacology 28: 226-234, 2003. 151. Swerdlow NR, Pitcher L, Noh HR, Shoemaker JM. Startle gating in rats is disrupted by chemical inactivation but not D2 stimulation of the dorsomedial thalamus. Brain Research 953: 246-254, 2002. 152. Swerdlow NR, Stephany N, Wasserman LC, Talledo J, Shoemaker J, Auerbach PP. Amphetamine effects on prepulse inhibition across species: Replication and parametric extension. Neuropsychopharmacology 28: 640-650, 2003.

153. Swerdlow NR, Wasserman LC, Talledo JA, Casas R, Bruins P, Stephany NL. Prestimulus modification of the startle reflex: Relationship to personality and physiological markers of dopamine function. Biol Psychology 62: 17-26, 2002. 154. Swerdlow NR, Stephany N, Wasserman LC, Talledo J, Sharp R, Auerbach PP. Dopamine agonists disrupt visual latent inhibition in normal males using a within-subject paradigm. Psychopharmacology 169: 314-320, 2003.

155. Powell SB, Geyer MA, Preece MA, Pitcher LK, Reynolds GP, Swerdlow NR. Dopamine depletion of the nucleus accumbens reverses isolation induced deficits in prepulse inhibition in rats. Neuroscience 119:233-40, 2003. 156. Swerdlow NR, Shoemaker JM, Platten A, Pitcher L, Goins J, Crain S. Heritable differences in the effects of amphetamine but not DOI on startle gating in albino and hooded outbred rat strains. Pharmacol Biochem Behav 75:191-7, 2003.

157. Swerdlow NR, Shoemaker JM, Auerbach PP, Pitcher L, Goins J, Platten A. Heritable differences in the dopaminergic regulation of sensorimotor gating: II. Temporal, pharmacologic and generational analyses of apomorphine effects on prepulse inhibition. Psychopharmacology 174: 452-462, 2004. 158. Swerdlow NR, Shoemaker JM, Platten A, Pitcher L, Goins J, Auerbach PP. Heritable differences in the dopaminergic regulation of sensorimotor gating: I. Apomorphine effects on startle gating in albino and hooded outbred rat strains and their F1 and N2 progeny. Psychopharmacology 174: 441-451, 2004.

159. Swerdlow NR, Shoemaker JM, Noh HR, Ma L, Gaudet I, Munson M, Crain S, Auerbach PP. The ventral hippocampal regulation of prepulse inhibition and its disruption by apomorphine in rats are not mediated via the fornix. Neuroscience 123:675-85: 2004. 160. Swerdlow NR, Shoemaker JM, Crain S, Goins J, Onozuka K, Auerbach PP. Sensitivity to drug effects on prepulse inhibition in inbred and outbred rat strains. Pharmacol Biochem Behav 77:291-302, 2004.

161. Swerdlow NR, Talledo J, Shoemaker JM, Codon K, Goins J, Auerbach PP. Weak prepulses inhibit but do not elicit startle in rats and humans. Biological Psychiatry 55:1195-8, 2004.

162. Swerdlow NR, Stephany S, Wasserman LC, Talledo J, Sharp R, Minassian A, Auerbach PP. Intact visual latent inhibition in schizophrenia patients in a within-subject paradigm. Schizophrenia Research 72: 169-183, 2005. 163. Swerdlow NR, Talledo JA, Braff DL. Startle modulation in Caucasian-Americans and Asian-Americans: A prelude to genetic/endophenotypic studies across the “Pacific Rim”. Psychiatric Genetics 15: 61-65, 2005.

164. Harte MK, Powell SB, Reynolds LM, Swerdlow NR, Geyer MA, Reynolds GP. Reduced N-acetylaspartate in the temporal cortex of rats reared in isolation. Biol Psychiatry 56: 296-9, 2004.

165. Swerdlow NR, Stephany NL, Talledo J, Light G, Braff DL, Bayens D, Auerbach PP. Prepulse inhibition of perceived stimulus intensity: Paradigm assessment. Biol Psychology 69: 133-47, 2005.

166. Swerdlow NR, Sutherland AN. Preclinical models relevant to Tourette Syndrome. Adv Neurol. 99: 69-88, 2006.

167. Braff DL, Light GA, Ellwanger J, Sprock J, Swerdlow NR. Female schizophrenia patients have prepulse inhibition deficits. Biol Psychiatry 57: 817-820, 2005.

168. Swerdlow NR, Kuczenski R, Goins JC, Crain SK, Ma LT, Bongiovanni MJ, Shoemaker JM. Neurochemical analysis of rat strain differences in the startle gating-disruptive effects of dopamine agonists. Pharmacol Biochem Behav 80: 203-211, 2005. 169. Swerdlow NR. Much ado about (almost) nothing: Response to ‘prepulse lost and regained’. Psychopharmacology 179: 893-894, 2005 (Commentary). 170. Hsieh MH, Swerdlow NR, Braff DL. Effects of background and prepulse characteristics on prepulse inhibition and prepulse facilitation: Implications for neuropsychiatric research. Biol Psychiatry 15: 59: 555-9, 2006.

171. Swerdlow NR. Tourette Syndrome: Current controversies and the battlefield landscape. Current Neurology and Neuroscience Reports 5: 329-331, 2005.

172. Swerdlow NR, Sutherland AN. Using animal models to develop therapeutics for Tourette Syndrome. Pharmacy Therapeutics 108: 281-293, 2005.

173. Shoemaker JM, Saint Marie RL, Bongiovanni MJ, Neary AC, Tochen LS, Swerdlow NR. Prefrontal D1 and ventral hippocampal NMDA regulation of startle gating in rats. Neuroscience 135: 385-394, 2005.

174. Swerdlow NR, Geyer MA, Shoemaker JM, Light GA, Braff DL, Stevens KE, Sharp R, Breier M, Neary A, Auerbach, PP. Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and N40 suppression in rats. Neuropsychopharmacology 31: 506-15, 2006. 175. Swerdlow NR, Krupin AS, Bongiovanni MJ, Shoemaker JM, Goins JC, Hammer Jr. RP. Heritable differences in the dopaminergic regulation of behavior in rats: Relationship to D2-like receptor G protein function. Neuropsychopharmacology 31: 506-513, 2006.

176. Swerdlow NR, Shoemaker JM. Bongiovanni MJ, Neary AC, Tochen LS, Saint Marie RL. Reduced startle gating after D1 blockade: Effects of concomitant D2 blockade. Pharmacology Biochemistry Behavior 82: 293-9, 2005. 177. Mink JW, Walkup J, Frey KA, Como P, Cath D, DeLong M, Erenberg G, Jankovic J, Juncos J, Leckman J, Swerdlow NR, Visser-Vandewall V, Vitek J, and the Tourette Syndrome Association. Patient Selection and Assessment Recommendations for Deep Brain Stimulation in Tourette Syndrome. Mov Disorder 21:1831-38, 2006

178. Swerdlow NR, Sprock J, Braff DL. Prepulse-elicited motor reactions do not differ between schizophrenia patients and normal comparison subjects. Behavioral Neuroscience 120: 224-7, 2006.

179. Swerdlow NR, Talledo Jo, Sutherland AN, Nagy D, Shoemaker JM. Antipsychotic effects on prepulse inhibition in normal “low gating” humans and rats. Neuropsychopharmacology 31: 2011-21, 2006.

180. Light GA, Hsu JL, Hsieh MH, Meyer-Gomes K, Sprock J, Swerdlow NR, Braff DL. Gamma band EEG oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol Psychiatry 60: 1231-1240, 2006. 181. Swerdlow NR, Bongiovanni MJ, Tochen L, Shoemaker JM. Separable noradrenergic and dopaminergic regulation of prepulse inhibition in rats: Implications for predictive validity and Tourette Syndrome. Psychopharmacology 186: 246-54, 2006.

182. Swerdlow NR, Light GA, Cadenhead KC, Sprock J, Hsieh MH, Braff DL. Startle gating deficits in a large cohort of patients with schizophrenia: Relationship to medications, symptoms, neurocognition and level of function. Arch Gen Psychiatry 63: 1325-1335, 2006. 183. Swerdlow NR, Shoemaker JM, Kuczenski R, Bongiovanni MJ, Neary AC, Tochen LS, Saint Marie RL. Forebrain D1 function and sensorimotor gating in rats: Effects of D1 blockade, frontal lesions and dopamine denervation. Neurosci Lett: 402: 40-5, 2006.

184. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. Neurophysiological endophenotypes of schizophrenia: The viability of selected candidate measures. Schizophr Bull: 33: 69-94, 2007. 185. Calkins ME, Dobie DJ, Cadenhead KS, Olincy A, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. The consortium on the genetics of endophenotypes in schizophrenia (COGS): model recruitment, assessment and endophenotyping methods for a multi-site collaboration. Schizophr Bull 33: 33-48, 2007.

186. Radant AD, Dobie DJ, Calkins ME, Olincy A, Braff DL, Cadenhead KC, Freedman R, Green MF, Greenwood TA, Gur RE, Light GA, Meichle SP, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang MT, Turetsky BI, Tsuang DW. Successful multi-site measurement of antisaccade performance deficits in schizophrenia. Schiz Research 89:320-9, 2007. 187. Saint Marie RL, Neary AC, Shoemaker JM, Swerdlow NR. The effects of apomorphine and d-amphetamine on striatal c-Fos expression in Sprague-Dawley and Long Evans rats and their F1 progeny. Brain Res 1119: 203-14, 2006.

188. Braff DL, Light GA, Swerdlow NR. Prepulse inhibition and P50 suppression are both deficient but not correlated in schizophrenia patients. Biological Psychiatry 61:1204-7, 2007.

189. Mink JW, Hollenbeck PJ, Swerdlow NR, Levi-Pearl S. Tourette Syndrome Research. J Child Neurol 21: 629, 2006 (Guest Editorial).

190. Swerdlow NR, Shoemaker JM, Bongiovanni M, Neary A, Tochen L, Saint Marie RL. Strain differences in the disruption of prepulse inhibition of startle after systemic and intra-accumbens amphetamine administration. Pharmacol Biochem Behav 87:1-10, 2007. 191. Metzger KL, Shoemaker JM, Kahn JB, Maxwell CR, Liang Y, Tokarczyk J, Kanes SJ, Hans M, Lowman AM, Nily D, Winey KI, Swerdlow NR, Siegel SJ. Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits. Psychopharmacology 190: 201-11, 2007.

192. Light GA, Swerdlow NR, Braff DL. Preattentive sensory processing is associated with cognitive and psychosocial functioning in healthy adults. J Cog Neurosci 19:1624-32, 2007.

193. Swerdlow NR, Sprock J, Light GA, Cadenhead K, Calkins ME, Dorcas DJ, Freedman RR, Green MF, Greenwood TA, Gur RE, Mintz J, Olincy A, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever, LJ, Silverman JM, Stone WS, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Multi-site studies of acoustic startle and prepulse inhibition in humans: Initial experience and methodological considerations based on studies by the Consortium on the Genetics of Schizophrenia. Schiz Research 92:237-51, 2007. 194. Greenwood TA, Braff DL, Light GA, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R, Green MF, Gur RE, Gur RC, Mintz J, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Schork NJ. The Consortium on the Genetics of Schizophrenia (COGS): Initial Heritability Analyses of Endophenotypic Measures for Schizophrenia. Arch Gen Psychiatry 64:1242-50, 2007.

195. Harte MK, Powell SB, Swerdlow NR, Geyer MA, Reynolds GP. Deficits in parvalbumin and calbindin immunoreactive cells in the hippocampus of isolation reared rats. J Neural Transmission 114:893-8, 2007.

196. Swerdlow NR, Blumenthal TD, Sutherland AN, Weber E, Talledo JA. Effects of prepulse intensity, duration, and bandwidth on perceived intensity of startling acoustic stimuli. Biol Psychol 74: 389-95, 2007.

197. Swerdlow NR, Breier M, Mora AB, Ko D, Shoemaker JM. A novel rat strain with enhanced sensitivity to the effects of dopamine agonists on startle gating. Pharmacol Biochem Behav 88:280-90, 2007 198. Weber MA, Swerdlow NR. Rat strain differences in startle gating-disruptive effects of apomorphine occur with both acoustic and visual prepulses. Pharmacol Biochem Behav 88:306-11, 2007 199. Shilling PD, Saint Marie RL, Shoemaker JM, Swerdlow NR. Strain differences in the gating-disruptive effects of apomorphine: Relationship to gene expression in nucleus accumbens signaling pathways. Biological Psychiatry 63: 748-58, 2008.

200. Braff DL, Greenwood TA, Swerdlow NR, Light GA, Schork NJ, the Investigators of the Consortium on the Genetics of Schizophrenia. Advances in endophenotyping schizophrenia. World Psychiatry 7:11-18, 2008. 201. Swerdlow NR*, Weber M*, Qu Y, Light GA, Braff DL. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology 199:331-88, 2008 (* equal contributions)

202. Horan WP, Braff DL, Nuechterlein KH, Sugar CA, Cadenhead KS, Calkins MD, Dobie DJ, Freedman R, Greenwood TA, Gur RE, Gur R, Light GA,, Mintz J, Olincy A, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Green MF. Verbal Working Memory Impairments in Individuals with Schizophrenia and Their First-Degree Relatives: Findings From the Consortium on the Genetics of Schizophrenia. Schiz Research 103:218-28, 2008. 203. Qu Y, Swerdlow NR, Weber M, Stouffer D, Parsons LH Quinelorane, a dopamine D3/D2 receptor agonist, reduces prepulse inhibition of startle and ventral pallidal GABA efflux: Time course studies. Pharmacol Biochem Behav 90: 686-90, 2008.

204. Weber M, Chang WL, Breier M, Ko D, Swerdlow NR. Heritable strain differences in sensitivity to the startle gating-disruptive effects of D2 but not D3 receptor stimulation. Behav Pharmacol 19:786-95, 2008. 205. Turetsky BI, Greenwood TA, Olincy A, Radant AD, Braff DL, Cadenhead KS, Dobie DJ, Freedman R, Green MF, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ,

Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Calkins ME. Abnormal Auditory N100 Amplitude: A Heritable Endophenotype in First-Degree Relatives of Schizophrenia Probands. Biological Psychiatry 64:1051-9, 2009. 206. Weber M, Breier M, Ko D, Thangaraj N, Marzan DE, Swerdlow NR. Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine. Psychopharmacology 203:723-35, 2009. 207. Swerdlow NR, van Bergeijk DP, Bergsma F, Weber E, Talledo J. The effects of memantine on prepulse inhibition. Neuropsychopharmacology 34:1854-64, 2009. 208. Talledo J, Sutherland Owens A, Schortinghuis T, Swerdlow NR. Amphetamine effects on startle gating in normal women and female rats. Psychopharmacology 204:165-75, 2009. 209. Swerdlow NR, Talledo JA. Effects of the first prepulse on the blink response to a startling noise. Behavioral Neuroscience 123:607-13, 2009. 210. Weber M, Chang WL, Park PE, Durbin JP, Luedtke RL, Mach RH, Swerdlow NR (2009). Using prepulse inhibition to detect functional D3 receptor antagonism: Effects of WC10 and WC44. Pharmacol Biochem Behav 93:141-7, 2009

211. Swerdlow NR, Lelham SA, Sutherland Owens AN, Chang WL, Sassen SDT, Talledo JA. Pramipexole effects on startle gating in rats and normal men. Psychopharmacology 205: 689-698, 2009.

212. Qu Y, Saint Marie RL, Breier MR, Ko D, Stouffer D, Parsons LH, Swerdlow NR. Neural basis for a heritable phenotype: Differences in the effects of apomorphine on startle gating and ventral pallidal GABA efflux in male Sprague Dawley and Long Evans rats. Psychopharmacology 207: 271-280, 2009. 213. Miller EJ, Saint Marie RL Breier MR, Swerdlow NR. Pathways from the ventral hippocampus and caudal amygdala to forebrain regions that regulate sensorimotor gating in the rat. Neuroscience 165: 601-11, 2010.

214. Chang WL, Geyer MA, Buell MR, Weber M, Swerdlow NR. The effects of pramipexole on prepulse inhibition and locomotor activity in C57BL/6J mice. Behav Pharmacol 21: 135-143, 2010.

215. Breier MR, Lewis B, Shoemaker JM, Light GA, Swerdlow NR. Sensory and sensorimotor gating-disruptive effects of apomorphine in Sprague Dawley and Long Evans rats. Behav Brain Res 208: 560-565, 2010. 216. Radant A, Dobie D, Calkins M, Olincy A, Braff D, Cadenhead K, Freedman R, Green M, Greenwood T, Gur R, Gur R, Light G, Meichle S, Millard S, Mintz J, Nuechterlein K, Schork N, Seidman L, Siever L, Silverman J, Stone W, Swerdlow N, Tsuang M, Turetsky B, Tsuang D. Antisaccade performance in schizophrenia patients, their first-degree biological relatives, and community comparison subjects: Data from the COGS study. Psychophysiology 47: 846-56, 2010.

217. Weber M, Chang WL, Breier M, Yang A, Millan MM, Swerdlow NR. The effects of the dopamine D2 agonist sumanirole on prepulse inhibition in rats. Eur Neuropsychopharm 20: 421-5, 2010.

218. Olincy A, Braff DL, Adler LE, Cadenhead KS, Calkins ME, Dobie DJ, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Wagner BD, Freedman R. Inhibition of the P50 cerebral evoked response to repeated auditory Sstimuli: Results from the Consortium on Genetics of Schizophrenia. Schiz Res 119: 175-182, 2010. 219. Chang WL, Swerdlow NR, Breier MR, Thangaraj N, Weber M. Parametric approaches towards understanding the effects of the preferential D3 receptor agonist pramipexole on prepulse inhibition in rats. Pharmacol Biochem Behav 95:473-8, 2010.

220. Saint Marie RL, Miller EJ, Breier MR, Weber M, Swerdlow NR. Projections from ventral hippocampus to medial prefrontal cortex but not nucleus accumbens remain functional after fornix lesions in rats. Neuroscience 168:498-504, 2010. 221. Stone WS, Giuliano AJ, Tsuang MT, Braff DL, Cadenhead KS, Calkins ME, Dobie DJ, Faraone SV, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Olincy A, Radant, AD, Roe AH, Schork NJ, Siever LJ, Silverman JM, Swerdlow NR, Thomas AR, Tsuang DW, Turetsky BI, Seidman LJ. Group and site differences on the California Verbal Learning Test in persons with schizophrenia and their first-degree relatives: Findings from the Consortium on the Genetics of Schizophrenia (COGS). Schiz Research 128: 102-110, 2011. 222. Sutherland Owens AN, Miguel EC , Swerdlow NR. Sensory gating scales and premonitory urges in Tourette syndrome. Scientific World Journal 11: 736-41, 2011. 223. Greenwood TA, Lazzeroni LC, Murray SS, Cadenhead KS, Calkins ME, Dobie DJ, Green MF, Gur RE, Hardiman G, Kelsoe JR, Leonard S, Light GA, Nuechterlein KH, Olincy A, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Freedman R, Braff DL. Analysis of 94 Candidate Genes and Twelve Endophenotypes for Schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry 168: 930-46, 2011.

224. Swerdlow NR, Breier MR, Saint Marie RL. Probing the molecular basis for an inherited sensitivity to the startle-gating disruptive effects of apomorphine in rats. Psychopharmacology 216: 401-10, 2011.

225. Swerdlow NR. Are we studying and treating schizophrenia correctly? Schiz Research 130: 1-10, 2011.

226. Chang WL, Breier MR, Yang A, Swerdlow NR. Disparate effects of pramipexole on locomotor activity and sensorimotor gating in Sprague Dawley rats. Pharmacol Biochem Behav 99: 634-8, 2011.

227. Swerdlow NR. Beyond antipsychotics: Pharmacologically-augmented cognitive therapies (PACTs) for schizophrenia Neuropsychopharm 37: 310-311, 2011.

228. Chang WL, Weber M, Breier MR, Saint Marie RS, Hines SR, Swerdlow NR. Stereochemical and neuroanatomical selectivity of pramipexole effects on sensorimotor gating in rats. Brain Research 1437: 69-76, 2012. 229. Greenwood TA, Light GA, Swerdlow NR, Radant AD, Braff DL. Association analysis of 94 candidate genes and schizophrenia-related endophenotypes. PLoS ONE 7(1): e29630, 2012. 230. Kirihara K, Rissling AJ, Swerdlow NR, Braff DL, Light GA. Hierarchical organization of gamma and theta oscillatory dynamics in schizophrenia. Biological Psychiatry 71: 873-880, 2012. 231. Swerdlow NR, Light GA, Breier MR, Shoemaker JM, Saint Marie RL, Neary AC, Geyer MA, Stevens KE, Powell SB. Sensory and sensorimotor gating deficits after neonatal ventral hippocampal lesions in rats. Developmental Neuroscience 34: 240-9, 2012.

232. Swerdlow NR, Shilling PD, Breier M, Trim RS, Light GA, Saint Marie RL. Fronto-temporal-mesolimbic gene expression and heritable differences in amphetamine-disrupted sensorimotor gating in rats. Psychopharmacology 224: 349-362, 2012. 233. Light GA, Swerdlow NR, Rissling AJ, Radant A, Sugar C, Sprock J, Pela, M, Geyer MA, Braff DL. Validation of candidate endophenotypes for use in genomic and clinical outcome studies of schizophrenia. PLoS ONE 7: e39434, 2012.

234. Rissling AJ, Braff DL, Swerdlow NR, Hellemann G, Rassovsky Y, Sprock J, Pela M, Light GA. Disentangling early sensory information processing deficits in schizophrenia. Clin Neurophysiol 123: 1942-1949, 2012.

235. Chou HH, Talledo J, Lamb S, Thompson W, Swerdlow NR. Amphetamine effects on MATRICS Consensus Cognitive Battery performance in healthy adults. Psychopharmacology 227: 165-76, 2012.

236. Calkins ME, Ray A, Gur RC, Freedman R, Green MF, Greenwood TA, Light GA, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar C, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL, Lazzeroni LC, Gur RE. Sex differences in familiality effects on neurocognitive performance in schizophrenia. Biological Psychiatry 73: 976-84, 2013.

237. Swerdlow NR. Studies of prepulse inhibition of startle, with particular relevance to the pathophysiology or treatment of Tourette Syndrome. Neuroscience & Biobehavioral Reviews 37: 1150-6, 2013. 238. Amitai N, Weber M, Swerdlow NR, Sharp RF, Breier M, Halberstadt AL, Young JW. A novel visuospatial priming task for rats with relevance to Tourette Syndrome and modulation of dopamine levels. Neuroscience & Biobehavioral Reviews 37: 1139-49, 2013.

239. Swerdlow NR, Hines SR, Herrera SD, Weber M, Breier MR. Opposite effects of tolcapone on amphetamine-disrupted startle gating in low vs. high COMT-expressing rat strains. Pharmacol Biochem Behav 106: 128-131, 2013. 240. Greenwood TA, Swerdlow NR, Gur RE, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R, Green MF, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Ray A, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Light GA, Braff DL. Genome-Wide Linkage Analyses of 12 Endophenotypes for Schizophrenia From the Consortium on the Genetics of Schizophrenia. Am J Psychiatry. 170: 521-32, 2013.

241. Swerdlow NR, Powell SB, Breier MR, Hines SR, Light GA. Coupling of gene expression in medial prefrontal cortex and nucleus accumbens after neonatal ventral hippocampal lesions accompanies deficits in sensorimotor gating and auditory processing in rats. Neuropharmacology 75C: 38-46, 2013. 242. Gulsuner S, Walsh T, Watts AC, Lee MK, Thornton AM, Casadei1 S, Rippey C, Shahin H, Consortium on the Genetics of Schizophrenia (COGS), PAARTNERS Study Group, Nimgaonkar VL, Go RCP, Savage RM, Swerdlow NR, Gur RE, Braff DL, King M-C, McClellan JM. Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell 154: 518-29, 2013.

243. Swerdlow NR, Light GA, Trim RS, Breier MR, Hines SR, Powell SB. Forebrain gene expression predicts deficits in sensorimotor gating after isolation rearing in male rats. Behavioural Brain Research 257:118-28, 2013. 244. Perez VB, Swerdlow NR, Braff DL, Naatanen R, Light GA. Using biomarkers to inform diagnosis, guide treatments and track response to interventions in psychotic illnesses. Biomarkers Med 8:9-14, 2014. 245. Swerdlow NR, Light GA, Sprock J, Calkins ME, Greene MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Ray A, Seidmani LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuanga MT, Turetsky BI, Braff DL. Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS. Schizophrenia Research 152:503-12, 2013. 246. Light GA, Greenwood TA, Swerdlow NR, Calkins ME, Freedman R, Green MF, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Comparison of the heritability of schizophrenia and endophenotypes in the COGS-1 family study. Schiz Bull (in press) 2014. 247. Tsuang D, Esterberg M, Braff D, Calkins M, Cadenhead K, Dobie D, Freedman R, Green MF, Greenwood T, Gur R, Gur R, Horan W, Lazzeroni LC, Light GA, Millard SP, Olincy A, Nuechterlein K, Seidman L, Siever L, Silverman J, Stone W, Sprock J, Sugar C, Swerdlow N, Tsuang M, Turetsky B,

Radant A. Is there an association between advanced paternal age and endophenotype deficit levels in schizophrenia? PLoS One 9(2):e88379, 2014.

248. Schmeidler J, Lazzeroni LC, Swerdlow NR, Ferreira RP, Braff DL, Calkins ME, Cadenhead KS, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Olincy A, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, StoneWS, Sprock J, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Silverman JM. Paternal age of schizophrenia probands and endophenotypic differences from unaffected siblings. Psychiatry Research (in press) 2014. 249. Swerdlow NR, Gur RE, Braff DL. Consortium on the Genetics of Schizophrenia (COGS) Assessment of Endophenotypes for Schizophrenia: An Introduction to this Special Issue of Schizophrenia Research. Schizophrenia Research (in press) 2014.

250. Lee J, Green MF, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Verbal Working Memory in Schizophrenia: The Moderating Role of Smoking Status and Antipsychotic Medications. Schizophrenia Research, Special Issue on Endophenotypes and Schizophrenia. Schizophrenia Research (in press) 2014. -------------------------

251. Stone WS, Braff DL, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Nuechterlein KH, Radant AD, Siever LJ, Silverman JM, Sprock J, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Seidman LJ. CVLT-II Performance in Schizophrenia as a Function of Ascertainment Strategy: Comparing the first and second phases of the Consortium on the Genetics of Schizophrenia (COGS). Schizophrenia Research, Special Issue on Endophenotypes and Schizophrenia. Submitted, June 2014.

252. Radant AD, Millard SP, Braff D, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Gur RE, Gur Rc, Lazzeroni L, Light GA, Meichle S, Nuechterlein KH, Olincy A, Seidman LJ, Siever L, Silverman J, Stone WS, Swerdlow NR, Sugar C, Tsuang MT, Turestsky BI, Tsuang DW. Robust differences in antisaccade performance exist between COGS schizophrenia cases and controls regardless of recruitment strategies. Schizophrenia Research, Special Issue on Endophenotypes and Schizophrenia. Submitted, June 2014.

253. Gur RC, Braff DL, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Lazzeroni LC, Light GA, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Gur RE. Neurocognitive performance in family-based and case-control studies of schizophrenia. Schizophrenia Research, Special Issue on Endophenotypes and Schizophrenia. Submitted, June 2014. 254. Light G, Swerdlow NR, Thomas ML, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Pela M, Radant AD, Seidman LJ, Sharp RF, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Braff DL, Turetsky BI. Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: Characterization of demographic, clinical, cognitive, and functional correlates in the COGS-2. Schizophrenia Research, Special Issue on Endophenotypes and Schizophrenia. Submitted, June 2014. 255. Turetsky BI, Dress EM, Braff DL, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Light G. Clinical and socio-demograhic factors influence the utility of P300 as a schizophrenia endophenotype and predictive biomarker. Schizophrenia Research, Special Issue on Endophenotypes and Schizophrenia. Submitted, June 2014.

256. Nuechterlein KH, Green MF, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR,

Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Attention/vigilance in schizophrenia: Performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS). Schizophrenia Research, Special Issue on Endophenotypes and Schizophrenia. Submitted, June 2014. 257. Seidman LJ, Hellemann G, Nuechterlein KH, Greenwood TA, Braff DL, Cadenhead KS, Calkins ME, Freedman R, Gur RE, Gur RC, Lazzeroni LC, Light GA, OlincyA, Radant AD, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar C, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Green MF. Factor structure and heritability of endophenotypes in schizophrenia: Findings from the Consortium on the Genetics of Schizophrenia (COGS-1). Schizophrenia Research, Special Issue on Endophenotypes and Schizophrenia. Submitted, June 2014. Book Chapters

1. Koob GF, Vaccarino FJ, Amalric M, Swerdlow NR. Neural substrates for opiate activation and reinforcement, in S. Fischer, A. Raskin and E.H. Uhlenhuth (Eds.), Cocaine: Behavioral and Clinical Aspects. Oxford University Press, 1987, pp 80-108. 2. Ruegg R, Zisook S, Swerdlow N. Depression in the aged: An overview, in D Jeste and S Zisook (eds), Psychosis and Depression in the Elderly. Psychiat Clin North Amer. WB Saunders, 1988, pp 83-108. 3. Swerdlow NR, Koob G, Geyer M, Mansbach R, Braff D. A cross-species model of psychosis, in P Simon, P Soubrie and D Widlocher (eds), Animal Models of Psychiat Disorders. Karger, 1988, pp 1-18. 4. Koob GF, Swerdlow NR. The functional output of the mesolimbic dopamine system, in P.W. Kalivas and C.B. Nemeroff (Eds.), The Mesocorticolimbic Dopamine System. Ann New York Acad Sci, Vol. 537, New York Acad Sci Press, 1988, pp. 216-237.

5. Swerdlow NR, Gilbert D, Koob GF. Conditioned drug effects on spatial preference: critical evaluation, in A.A. Boulton, G.B. Baker and A.J. Greenshaw (Eds.), Neuromethods: Psychopharmacology. Vol. 13: 399 - 446. Humana Press (Clinton, N.J.) 1989. 6. Pulvirenti L, Swerdlow NR, Hubner CB, Koob GF. The role of limbic-accumbens-pallidal circuitry in the activating and reinforcing properties of psychostimulant drugs, in P. Wilner (Ed.), Proceedings of the 1989 Malta Workshop on Dopamine, 1991, pp 131-140.

7. Koob GF, Swerdlow NR, Vaccarino FJ, Hubner C, Pulvirenti L, Weiss F. Functional output of the basal forebrain, in T.C. Napier, P. Kalivas and I. Hanin (Eds.), The Basal Forebrain: Anatomy to Function. Plenum Press (New York, N.Y.) 1991, pp. 291-305. 8. Swerdlow NR, Braff DL, Geyer MA. Limbic cortico-striato-pallido-pontine substrates of sensorimotor gating in animal models and psychiatric disorders, in P Kalivas and C Barnes (eds), The mesolimbic motor circuit and its role in neuropsychiatric disorders. (CRC Press)1993, pp. 311-328.

9. Swerdlow NR. Behavioral pharmacology. in Elliot GR, Ciaranello RD and Barchas JD (Eds.), Psycho-pharmacology from theory to practice, 2nd edition. Oxford Univ Press (New York, NY) 1993.

10. Swerdlow NR, Braff DL, Bakshi VP, Geyer MA. An animal model of sensorimotor gating deficits in schizophrenia predicts antipsychotic drug action, in Csernansky J (Ed.) Handbook of Experimental Pharmacology. Springer (New York, NY) 1998, pp. 289-312. 11. Dawson ME, Schell AM, Swerdlow NR, Filion DL. Cognitive, clinical and neuroscience implications of startle modification, In PJ Lang, RF Simons, MT Balaban (Eds.), Attention and orienting: Sensory and motivational processes. Erlbaum (Mahwah, NJ) 1997, pp. 257-279.

12. Swerdlow NR. Cortico-striatal substrates of cognitive, motor and sensory gating: Speculations and implications for psychological function and dysfunction, In J Panksepp (Ed.) Advances in Biological Psychiatry (Vol. 2). JAI Press Inc. (Greenwich, CT) pp. 179-208, 1996.

13. Swerdlow NR, Perry W. Endocrine regulation of information processing: Animal models and implications for schizophrenia. In: Infertility and Reproductive Medicine Clinics of North America, W.B. Saunders (Philadelphia, PA) pp. 279-296, 1996. 14. Geyer MA, Swerdlow NR. Measurement of startle response, prepulse inhibition, and habituation. in JN Crawley amd P Skolnick (Eds.), Current Protocols in Neuroscience, John Wiley & Sons (New York, NY), unit 8.7, pp. 1-15, 1998.

15. Swerdlow NR, Geyer MA. Neurophysiology and neuropharmacology of short lead interval startle modification, In Dawson ME, Schell A, Boehmelt A, Startle Modification: Implications for Neuro-science, Cognitive Science, and Clinical Science, Cambridge Univ. Press (Cambridge, UK), pp. 114-133, 1999. 16. Geyer MA, Markou A, Swerdlow NR. Contemporary animal models for testing psychopharmacological impact, in Indo-US Workshop on Traditional Medicine and Mental Health and Neurosciences. NIMH, Bangalore, India ,1999.

17. Geyer MA, Braff DL, Swerdlow NR. Startle response measures of information processing in animals: Relevance to schizophrenia. In M Haug, RE Whalen (Eds.), Animal Models of Human Emotion and Cognition. APA Books (Washington, DC) pp. 103-116, 1999. 18. Geyer MA, Swerdlow NR. Multiple transmitters modulate prepulse inhibition of startle: relevance to schizophrenia. In Paloma T, Beninger R, Archer T (Eds), Interactive Monoaminergic Disorders. Fundacion Cerebro y Mente (Madrid, Spain) 1999, pp. 343-354.

19. Perry W, Swerdlow NR, McDowell JE, Braff DL. Schizophrenia and frontal lobe functioning: Evidence from neuropsychology, cognitive neuroscience and psychophysiology. In Cummings J, Miller B (Eds), The Frontal Lobes. Guilford Press (New York, NY) 1998, pp. 509-521. 20. Swerdlow NR, Young AB. Neuropathology in Tourette Syndrome: An Update. In Cohen DJ, Jankovic J, Goetz CG (eds) Tourette Syndrome: Edition 1, Lippincott Williams & Wilkins (Philadelphia, PA), 2001. 21. Geyer MA, Swerdlow NR. Olanzapine in behavioral models of glutamatergic function. In PV Tran, FB Bymaster, N Tye (Eds), Olanzapine (Zyprexa) - A novel antipsychotic. Lippincott Williams & Wilkins (Philadelphia, PA), pp. 93-103, 2000.

22. Swerdlow NR. Blurry Spectrum Disorders. In Maj M, Sartorius N, Okasha A and Zohar J (Eds) Obsessive Compulsive Disorder. World Psychiatric Association Press (Chichester, UK) 2000, pp. 235-238.

23. Swerdlow NR, Leckman JF. Tourette Syndrome and related tic disorders. In Davis KL, Charney D, Coyle JT, Nemeroff C (Eds), Neuropsychopharmalogy: The Fifth Generation of Progress, ACNP (Lippincott, Williams & Wilkins, Baltimore), pp. 1685-1698, 2002. 24. Swerdlow NR. Obsessive-compulsive disorder and tic syndromes. Med Clin North Am 85:735-755, 2001. 25. Baxter LR, Ackermann RF, Swerdlow NR, Brody A, Saxena S, Schwartz JM, Gregoritch JM, Stoessel P, Phelps ME. Specific brain system mediation of obsessive-compulsive disorder responsive to either medication or behavior therapy. In WK Goodman, MV Rudorfer and JD Maser (Eds.) Obsessive Compulsive Disorder: Contemporary issues in treatment, Lawrence Erlbaum Assoc., Inc. (Mahwah, NJ) 2000, pp. 573-609.

26. Swerdlow NR. Afterword. In Handler L. Twitch and Shout: A Touretter’s Tale. University of Minnesota Press (Minneapolis, MN), pp. 205-218, 2004.

27. Swerdlow NR. Overview of Tourette Syndrome, In L Squire, FE Bloom, and SK McConnell, Fundamental Neuroscience, 2nd Edition, Elsevier Press, pp. 837-838, 2002.

28. Swerdlow NR. Prepulse inhibition of startle in humans and laboratory models. New Encyclopedia of Neuroscience. Elsevier Press (Oxford, UK) 2007.

29. Qu Y, Weber MA, Swerdlow NR. The nucleus accumbens regulation of sensorimotor gating in animal models and neuropsychiatric disorders. The Nucleus Accumbens: Neurotransmitters and Related Behaviours. Research Signpost (Kerala, India) 2009. 30. Swerdlow NR, Weber M. Using animal models to understand Tourette Syndrome. In: Kompoliti K, Verhagen L, Goetz CG (eds). Encyclopedia of Movement Disorders. Elsevier: Oxford, Chapter 9, 2008. 31. Swerdlow NR. A cautionary note on latent inhibition in schizophrenia: Are we ignoring relevant information? In: Weiner I, Lubow R (eds) Latent Inhibition: Data, Theories, and Applications to Schizophrenia. Cambridge University Press (Cambridge, UK), pp. 448-456, 2010.

32. Light GA, Williams LE, Minow F, Sprock J, Rissling A, Sharp R, Swerdlow NR, Braff DL. Electroencephalography (EEG) and Event-Related Potentials (ERP's) with Human Participants. Current Protocols in Neuroscience, Chapter 6:Unit 6.25.1-24, 2010. 33. Swerdlow NR. Integrative circuit models and their implications for the pathophysiologies and treatments of the schizophrenias. The Behavioral Neurobiology of Schizophrenia and its Treatment. in "Current Topics in Behavioral Neuroscience", Springer, 2010, pp. 555-586.

34. Swerdlow NR. The developing field of schizophrenia research, The Behavioral Neurobiology of Schiz-ophrenia and its Treatment. In "Current Topics in Behavioral Neuroscience", Springer, 2010, pp. v-vii.

35. Chou H-H, Twamley E, Swerdlow NR. Towards medication-enhancement of cognitive interventions in schizophrenia. In “Current Antipsychotics,” Handbook of Experimental Pharmacology (Gross G, Geyer MA (Eds.)), Springer-Verlag (Berlin, Germany) 213: 81-111, 2012. 36. Bhakta SG, Swerdlow NR. Prefrontal cortex dysfunction and neurocognitive deficits in schizophrenia: Targets of opportunity. In: RO Collins & JL Adams (Ed.), Prefrontal Cortex: Developmental Differences, Executive and Cognitive Functions and Role in Neurological Disorders. Hauppauge NY, Nova Science Publishers, (in press), 2013. 37. Light GA, Swerdlow NR. Neurophysiological and psychophysiological biomarkers informing the clinical neuroscience of schizophrenia: Mismatch negativity event-related potential and prepulse inhibition of startle. In Bob, Boutros & Kumari (Eds.). In “Current Topics Behavioral Neuroscience”, Springer (in press) 2014 (PMID: 24850080). Books:

Swerdlow NR. Editor, The Behavioral Neurobiology of Schizophrenia and its Treatment. in "Current Topics in Behavioral Neuroscience", Springer, 2010 (664 pages).

Blogs: Swerdlow, NR. Genes and phenes: What do they mean? Schizophrenia Research Forum, 5/24/2011 www.schizophreniaforum.org/pap/annotation.asp?powID=149146#{F59C9A3E-E65C-4C96-9736-1F47D4B74E69}